Pre-made Ofatumumab benchmark antibody ( Whole mAb, anti-MS4A1/CD20 therapeutic antibody, Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Ofatumumab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ofatumumab,[9] sold under the brand name Arzerra among others, is a fully human monoclonal antibody to CD20, which appears to inhibit early-stage B lymphocyte activation. It is FDA approved for treating chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab (Campath) and for the treatment of multiple sclerosis. It has also shown potential in treating follicular lymphoma, diffuse large B cell lymphoma, rheumatoid arthritis. Ofatumumab is the first marketing application for an antibody produced by Genmab, as well as the first human monoclonal antibody which targets the CD20 molecule that will be available for patients with refractory CLL.